AbbVie Inc. Selling, General and Administrative Expense of Revenue

Selling, General and Administrative Expense of Revenue of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative Expense of Revenue for the quarter ending September 29, 2021 was 20.67% (a -6.09% decrease compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative Expense of Revenue decreased by -7.76%
  • Annual Selling, General and Administrative Expense of Revenue for 2020 was 21.58% (a 7.04% increase from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2019 was 20.16% (a -9.92% decrease from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2018 was 22.38% (a 8.17% increase from previous year)
  • Twelve month Selling, General and Administrative Expense of Revenue ending September 29, 2021 was 21.53% (a -0.83% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative Expense of Revenue decreased by -10.96% year-over-year
Trailing Selling, General and Administrative Expense of Revenue for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
21.53% 21.71% 24.14% 24.18%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative Expense of Revenue of AbbVie Inc.

Most recent Selling, General and Administrative Expense of Revenueof ABBV including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative Expense of Revenue of AbbVie Inc.

AbbVie Inc. Selling, General and Administrative Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 20.67% 22.01% 21.04%
2020 22.41% 21.31% 33.83% 19.67% 21.58%
2019 22.41% 19.54% 20.04% 21.46% 20.16%
2018 23.23% 23.3% 21.26% 22.57% 22.38%
2017 25.27% 20.83% 21.73% 21.0% 20.69%
2016 24.71% 21.47% 22.72% 22.74% 22.63%
2015 27.14% 24.8% 31.11% 29.23% 27.94%
2014 61.28% 31.78% 29.4% 29.37% 38.7%
2013 28.33% 27.07% 29.97% 28.57% 28.48%
2012 27.1% 24.07% 27.73% 29.88% 27.14%
2011 96.96% 0.0% 0.0% 30.23% 33.79%
2010 24.43%

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.